수술 후 통증 관리 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

Post Operative Pain Management Market size in 2026 is estimated at USD 45.29 billion, growing from 2025 value of USD 42.84 billion with 2031 projections showing USD 59.82 billion, growing at 5.72% CAGR over 2026-2031.

Steady adoption of multimodal analgesia, reimbursement incentives for non-opioid options, and long-acting regional techniques are accelerating demand across surgical specialties. Orthopedic, cardiovascular, and thoracic procedures anchor consumption, while Enhanced Recovery After Surgery (ERAS) protocols position local anesthetics and topical innovations for outsized growth. Cost-sensitive hospitals are trimming premium intravenous usage, yet AI-driven personalized dosing and digital pharmacy distribution continue to unlock efficiency gains. Competitive intensity is mounting as established pharmaceutical firms and biotech entrants vie to commercialize NaV1.8 inhibitors, extended-release nerve-block injectables, and smart transdermal systems.

Global Post-Operative Pain Management Market Trends and Insights

Growing Number of Surgical Procedures

Ambulatory surgery centers increased from 612 specialized pain-focused facilities in 2018 to more than 800 by 2023, signaling accelerating procedure volumes that heighten baseline demand for multimodal analgesia. Aging populations in developed economies fuel orthopedic and cardiovascular operations, driving consistent consumption of regional anesthetics and adjuvant agents. ERAS pathways have become mainstream, institutionalizing evidence-based protocols that reduce length of stay while safeguarding pain control. Regulatory guidance under United States Food and Drug Administration (FDA) labeling promotes standardized postoperative dosing, giving hospitals a clear compliance roadmap. As volumes rise, suppliers that streamline dosing complexity and inventory management stand to capture incremental share in the post operative pain management market.

Shift Toward Multimodal & Non-Opioid Protocols

January 2025 FDA approval of suzetrigine introduced the first NaV1.8 sodium-channel blocker class, delivering analgesia without opioid dependency risk. Clinical implementation demonstrates up to 50% opioid reduction while preserving equivalent Numeric Rating Scale scores, especially in joint replacement and thoracic resections. Reimbursement incentives under the NOPAIN Act bolster hospital adoption, and ultrasound-guided nerve blocks now complement pharmacologic regimens in routine practice. The changeover requires protocol re-training but yields fewer respiratory events, shorter recovery, and higher patient satisfaction, all driving measurable savings that enlarge the post operative pain management market.

Opioid Addiction Crisis & Tightening Regulations

Prescription-drug monitoring programs and updated Centers for Medicare & Medicaid Services (CMS) guidelines limit postoperative opioid days' supply, compounding administrative load for providers. Mandatory continuing-education curricula raise compliance costs and prompt conservative prescribing that may leave analgesic gaps in complex cases. While insurers increasingly cover non-opioid modalities, upfront acquisition prices remain higher, deterring broad adoption in smaller hospitals. The uncertain regulatory trajectory around opioid availability compels supply-chain contingencies, adding inventory expense. These factors collectively constrain near-term revenue expansion for opioid segments of the post operative pain management market.

Other drivers and restraints analyzed in the detailed report include:

1. Adoption of Long-Acting Regional/Nerve-Block Anesthetics
2. Expansion of Ambulatory Surgery Centers Creating Demand for Rapid-Recovery Analgesics
3. Hospital Cost-Containment Curbing Premium IV Formulations

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Local anesthetics produced the fastest 7.94% CAGR outlook from 2026-2031, outpacing opioid, NSAID, and COX-2 categories. Liposomal bupivacaine's broad labeling across orthopedic and abdominal surgeries showcases tangible opioid reductions and shortened length of stay. The post operative pain management market size for local anesthetics is expected to rise in lockstep with ERAS protocol penetration. Measured by revenue, opioids still commanded a 41.73% post operative pain management market share in 2025, yet the segment's future is capped by prescribing limits and social scrutiny. The mid-spectrum NSAID class benefits from inclusion in nearly every multimodal pathway, though gastrointestinal warnings temper growth. Novel NaV1.8 inhibitors will enter the mix, potentially shifting share by 2027 when follow-on molecules gain approval. Regional anesthesia pipeline depth underlines sustained attention to non-systemic mechanisms, reinforcing local anesthetics' strategic position.

Second-generation depot lidocaine and sustained-release ropivacaine implants may extend the category's duration edge, while together with adjuvant gabapentinoids and alpha-2 agonists they deliver synergistic analgesia without additive toxicity. As payers examine total-cost-of-care metrics, formularies increasingly prefer long-acting local anesthetics that reduce inpatient opioid rescue meds and readmissions. This economic story aligns manufacturers and providers on continuous utilization increases, underpinning the rising revenue share forecast for local anesthetics within the broader post operative pain management market.

Oral modalities retained 56.03% of 2025 sales, driven by established dosing familiarity and low per-unit cost. Microneedle and smart-patch advances, however, push topical market growth to a 7.25% CAGR through 2031, the fastest across all routes. Transdermal systems deliver consistent plasma levels, reduce nursing interventions, and support outpatient recovery, a pivotal advantage as surgeries shift to same-day settings. The post operative pain management market size tied to topical delivery should approach double-digit billion-dollar levels by 2030 if current adoption rates persist.

Injectables remain indispensable for immediate postoperative phases, especially in trauma and high- acuity cardiac cases requiring rapid onset. Yet hospitals' focus on pharmacy spend prompts tighter criteria for IV orders in favor of oral equivalents when tolerated. Depot nerve-block injectables prolong analgesia for major joints and spine surgery, cutting demand for systemic medications. Technology collaborations pair wearables with transdermal patches that modulate release via smartphone apps, enhancing personalization and adherence. Such integrated solutions differentiate suppliers in the competitive post operative pain management market.

The Post-Operative Pain Management Market Report is Segmented by Drug Class (Opioids, Nsaids, and More), Route of Administration (Injectable, Oral, and More), Surgery Type (Orthopedic, Cardiovascular & Thoracic, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America held 34.16% of global revenue in 2025 amid strong ERAS adoption, stringent opioid regulations, and reimbursement levers that favor non-opioid alternatives. FDA green-lights for NaV1.8 inhibitors and expanding ambulatory surgery center networks sustain demand, while payer scrutiny compels evidence-backed product selection. Health-system budgets topping USD 4 trillion ensure capacity for premium extended-release local anesthetics and AI-enabled dosing software, cementing the region's leadership position.

Asia-Pacific is advancing at a 6.55% CAGR as surgical volumes climb in China, India, Japan, and South Korea. National insurance expansions and hospital-modernization drives bring ERAS pathways to secondary cities, stimulating uptake of multimodal regimens. Domestic manufacturers leverage cost-competitive generics while partnering with multinationals for depot formulations, thereby broadening product access. Regulatory harmonization across ASEAN accelerates registration timelines, further enlarging the post operative pain management market footprint in the region.

Europe posts steady growth tied to unified clinical guidelines and ongoing opioid-sparring directives from the European Medicines Agency. Topical and regional anesthetic innovations gain traction in Scandinavian and DACH countries renowned for early technology adoption. Middle East & Africa and South America remain emergent, yet Gulf Cooperation Council investments and Brazil's public-sector procurements provide beachheads for premium analgesics. Collectively, these dynamics underline geographically balanced expansion potential for the post operative pain management market.

1. Abbvie
2. Heron Therapeutics
3. Cali Biosciences
4. Innocoll
5. Bayer
6. GlaxoSmithKline
7. Pacira BioSciences Inc.
8. Johnson & Johnson
9. AFT Pharmaceuticals
10. Alembic Pharmaceuticals
11. Cipla
12. SiteOne Therapeutics
13. Pfizer
14. Teva Pharmaceutical Industries
15. Endo International
16. Eli Lilly and Company
17. Novartis
18. Purdue Pharma
19. Mallinckrodt plc
20. Boston Scientific
21. Medtronic

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Number of Surgical Procedures
  • 4.2.2 Shift Toward Multimodal & Non-Opioid Protocols
  • 4.2.3 Adoption of Long-Acting Regional/Nerve-Block Anesthetics
  • 4.2.4 Expansion of Ambulatory Surgery Centers (ASCs) Creating Demand for Rapid-Recovery Analgesics
  • 4.2.5 AI-Driven Personalized Dosing Within ERAS Pathways
  • 4.2.6 Legislative Incentives for Non-Opioid Analgesic Reimbursement
• 4.3 Market Restraints
  • 4.3.1 Opioid Addiction Crisis & Tightening Regulations
  • 4.3.2 Hospital Cost-Containment Curbing Premium IV Formulations
  • 4.3.3 GI / Cardiovascular Risks of NSAIDs & Cox-2 Inhibitors
  • 4.3.4 Patent Cliffs on Key Extended-Release Formulations
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Drug Class
  • 5.1.1 Opioids
  • 5.1.2 NSAIDs
  • 5.1.3 COX-2 Inhibitors
  • 5.1.4 Local Anesthetics
  • 5.1.5 Adjuvant Analgesics
• 5.2 By Route of Administration
  • 5.2.1 Injectable
  • 5.2.2 Oral
  • 5.2.3 Topical / Transdermal
  • 5.2.4 Intrathecal / Epidural
  • 5.2.5 Inhalational
• 5.3 By Surgery Type
  • 5.3.1 Orthopedic
  • 5.3.2 Cardiovascular & Thoracic
  • 5.3.3 Abdominal & Gastrointestinal
  • 5.3.4 Obstetrics & Gynecology
  • 5.3.5 Ophthalmic & ENT
  • 5.3.6 Others
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 AbbVie (Allergan)
  • 6.3.2 Heron Therapeutics
  • 6.3.3 Cali Biosciences
  • 6.3.4 Innocoll
  • 6.3.5 Bayer AG
  • 6.3.6 GSK plc.
  • 6.3.7 Pacira BioSciences Inc.
  • 6.3.8 Johnson & Johnson (Janssen)
  • 6.3.9 AFT Pharmaceuticals
  • 6.3.10 Alembic Pharmaceuticals
  • 6.3.11 Cipla Inc.
  • 6.3.12 SiteOne Therapeutics
  • 6.3.13 Pfizer Inc.
  • 6.3.14 Teva Pharmaceutical Industries
  • 6.3.15 Endo International
  • 6.3.16 Eli Lilly & Co.
  • 6.3.17 Novartis AG
  • 6.3.18 Purdue Pharma
  • 6.3.19 Mallinckrodt plc
  • 6.3.20 Boston Scientific
  • 6.3.21 Medtronic

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment